GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Atrion Corp (NAS:ATRI) » Definitions » Peter Lynch Fair Value

Atrion (Atrion) Peter Lynch Fair Value

: N/A (As of Today)
View and export this data going back to 1972. Start your Free Trial

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.


The historical rank and industry rank for Atrion's Peter Lynch Fair Value or its related term are showing as below:


During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Atrion was 5.79. The lowest was 3.17. And the median was 3.79.


ATRI's Price-to-Peter-Lynch-Fair-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.53
* Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


Atrion Peter Lynch Fair Value Historical Data

The historical data trend for Atrion's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atrion Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Atrion Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Peter Lynch Fair Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Atrion's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atrion Price-to-Peter-Lynch-Fair-Value Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Atrion's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where Atrion's Price-to-Peter-Lynch-Fair-Value falls into.



Atrion Peter Lynch Fair Value Calculation

Atrion's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* N/A *11.446
=N/A

Atrion's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $11.45.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


Atrion  (NAS:ATRI) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 0 instead of 15 in this case.

Atrion's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=404.60/N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Atrion Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of Atrion's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Atrion (Atrion) Business Description

Traded in Other Exchanges
N/A
Address
One Allentown Parkway, Allen, TX, USA, 75002-4211
Atrion Corp develops and manufactures products for medical applications. Its fluid-delivery products contribute the largest proportion of revenue and include valves that can hold and release controlled amounts of fluids or gases and are often used in anesthesia and oncology applications. Atrion's cardiovascular products include the MPS2 Myocardial Protection System, which delivers fluids and medications, mixes drugs, and controls temperature and pressure during open-heart surgery. The cardiovascular business also sells cardiac-surgery vacuum relief valves, inflation devices, and other products used in heart surgery. The firm's ophthalmic products include medical devices that disinfect contact lenses. Atrion generates the majority of revenue in the United States.
Executives
Preston G Athey director ONE ALLENTOWN PKWY, ALLEN TX 75002
David A Battat officer: President & CEO 2700 HALKEY-ROBERTS PLACE NORTH, ST. PETERSBURG FL 33716-4103
Jeannette Bankes director ONE ALLENTOWN PARKWAY, ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Morgan Hugh J Jr director
Ronald Nicholas Spaulding director ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Cindy Ferguson officer: Officer/ CFO ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Jeffery Strickland officer: Vice President & CFO
Emile A Battat director, officer: Chairman ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Stupp John P Jr director STUPP JOHN P JR, #18 ST. ANDREWS DR., ST LOUIS MO 63124
Roger F Stebbing director
Ronald N Spaulding director C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Richard O Jacobson director ONE ALLENTOWN PARKWAY, C/O ATRION, ALLEN TX 75002
Maley John H P director 6 ROCK CREST LANE, SIGNAL MOUNTAIN TN 37377
Margaret Maxwell Zagel director C/O TELLABS OPERATIONS INC, 4951 INDIANA AVE, LISLE IL 60532

Atrion (Atrion) Headlines

From GuruFocus

Atrion Corporation Increases Quarterly Cash Dividend by 10%

By PurpleRose PurpleRose 08-22-2022

Atrion Corporation Declares Quarterly Cash Dividend

By GuruFocusNews GuruFocusNews 07-03-2022

Atrion Corporation Declares Quarterly Cash Dividend

By Value_Insider Value_Insider 11-14-2022

Atrion Corporation Declares Quarterly Cash Dividend

By GuruFocusNews GuruFocusNews 06-03-2022

Atrion Corporation Increases Quarterly Cash Dividend by 11%

By Marketwired Marketwired 08-30-2021

Atrion Corporation Declares Quarterly Cash Dividend

By PurpleRose PurpleRose 07-14-2022

Atrion Corporation Announces CFO Succession Plan

By GlobeNewswire GlobeNewswire 08-25-2022

Atrion Reports Second Quarter 2022 Results

By PurpleRose PurpleRose 08-08-2022